Please see this article describing a talk at the Cure SMA 2015 Researcher meeting related to the NN101 SMA Biomarker study. Speaking on initial results was Stephen Kolb, MD, from The Ohio State University. He is the principal investigator for the study.
The NN103 Study Team is pleased to announce the addition of 11 NeuroNEXT Clinical Study Sites (CSS) across the US. One CSS has already been activated for enrollment, and 10 more are in the process of being activated. This will bring the total number of enrolling clinical study sites to 26.
A Phase 2 Trial of Rituximab in Myasthenia Gravis (NN103)